Cite
HARVARD Citation
Rocconi, R. et al. (2021). Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL): A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial. Obstetrical & gynecological survey. 76 (3), pp. 151-152. [Online].